These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8115824)

  • 1. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor.
    Yarrington JT; Gibson JP; Dillberger JE; Hurst G; Lippert B; Sussman NM; Heydorn WE; Marler RJ
    Toxicol Pathol; 1993; 21(5):480-9. PubMed ID: 8115824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor.
    Gibson JP; Yarrington JT; Loudy DE; Gerbig CG; Hurst GH; Newberne JW
    Toxicol Pathol; 1990; 18(2):225-38. PubMed ID: 2399411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration.
    Valdizán EM; Armijo JA
    Biochem Pharmacol; 1992 May; 43(10):2143-50. PubMed ID: 1599502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin.
    John RA; Rimmer EM; Williams J; Cole G; Fowler LJ; Richens A
    Biochem Pharmacol; 1987 May; 36(9):1467-73. PubMed ID: 3579985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs.
    Weiss KL; Schroeder CE; Kastin SJ; Gibson JP; Yarrington JT; Heydorn WE; McBride RG; Sussman NM; Arezzo JC
    Neurology; 1994 Oct; 44(10):1944-9. PubMed ID: 7936252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of vigabatrin.
    Sabers A; Gram L
    Pharmacol Toxicol; 1992 Apr; 70(4):237-43. PubMed ID: 1608908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats.
    Butler WH; Ford GP; Newberne JW
    Toxicol Pathol; 1987; 15(2):143-8. PubMed ID: 3616399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA).
    Manor D; Rothman DL; Mason GF; Hyder F; Petroff OA; Behar KL
    Neurochem Res; 1996 Sep; 21(9):1031-41. PubMed ID: 8897466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma-vinyl GABA.
    Hammond EJ; Wilder BJ
    Gen Pharmacol; 1985; 16(5):441-7. PubMed ID: 2932363
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain.
    Peyster RG; Sussman NM; Hershey BL; Heydorn WE; Meyerson LR; Yarrington JT; Gibson JP
    Epilepsia; 1995 Jan; 36(1):93-100. PubMed ID: 8001516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between platelet and brain GABA transaminase inhibition by single and multiple doses of vigabatrin in rats.
    Valdizán EM; Armijo JA
    Epilepsia; 1991; 32(5):735-42. PubMed ID: 1915185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.
    Petroff OA; Rothman DL
    Mol Neurobiol; 1998 Feb; 16(1):97-121. PubMed ID: 9554704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of increasing doses of vigabatrin on platelet gamma-aminobutyric acid-transaminase and brain gamma-aminobutyric acid in rats.
    Valdizán EM; García AP; Armijo JA
    Eur J Pharmacol; 1999 Mar; 369(2):169-73. PubMed ID: 10206175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of the GABAergic effects of vigabatrin: is the time course of brain GABA related to platelet GABA-transaminase inhibition?
    Valdizán EM; García AP; Armijo JA
    Epilepsia; 1999 Aug; 40(8):1062-9. PubMed ID: 10448817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies of the influence of vigabatrin on the GABA system.
    Gram L; Larsson OM; Johnsen A; Schousboe A
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):13S-17S. PubMed ID: 2757904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of brain GABA levels with vigabatrin (gamma-vinylGABA) differentially affects GAD65 and GAD67 expression in various regions of rat brain.
    Sheikh SN; Martin DL
    J Neurosci Res; 1998 Jun; 52(6):736-41. PubMed ID: 9669322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of vigabatrin.
    Schechter PJ
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):19S-22S. PubMed ID: 2667604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of gamma-vinyl GABA on the GABAergic system in rats as studied by microdialysis.
    Jolkkonen J; Mazurkiewicz M; Lahtinen H; Riekkinen P
    Eur J Pharmacol; 1992 Dec; 229(2-3):269-72. PubMed ID: 1490526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats.
    Engelborghs S; Pickut BA; D'Hooge R; Wiechert P; Haegele K; De Deyn PP
    Arzneimittelforschung; 1998 Jul; 48(7):713-6. PubMed ID: 9706369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma-vinyl GABA: a new antiepileptic drug.
    Hammond EJ; Wilder BJ
    Clin Neuropharmacol; 1985; 8(1):1-12. PubMed ID: 3884148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.